The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).
N. Schmitz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
M. Nickelsen
Honoraria - Roche
Research Funding - Roche
M. Ziepert
No relevant relationships to disclose
M. Haenel
No relevant relationships to disclose
P. Borchmann
No relevant relationships to disclose
C. Schmidt
No relevant relationships to disclose
A. Viardot
No relevant relationships to disclose
M. Bentz
No relevant relationships to disclose
N. Peter
No relevant relationships to disclose
G. Ehninger
No relevant relationships to disclose
G. Doelken
No relevant relationships to disclose
L. H. Truemper
No relevant relationships to disclose
M. Loeffler
No relevant relationships to disclose
M. Pfreundschuh
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
B. Glass
Honoraria - Roche
Research Funding - Roche